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Abstract
Background: Intratumoral steroidogenesis and its potential relevance in castration‐
resistant prostate cancer (CRPC) and in cytochrome P450, family 17, subfamily A,
polypeptide 1 (CYP17A1)‐inhibitor treated hormone‐naïve and patients with CRPC are not
well established. In this study, we tested if substrates for de novo steroidogenesis
accumulating during CYP17A1 inhibition may drive cell growth in relevant preclinical
models.
Methods: PCa cell lines and their respective CRPC sublines were used to model CRPC in
vitro. Precursor steroids pregnenolone (Preg) and progesterone (Prog) served as substrate
for de novo steroid synthesis. TAK700 (orteronel), abiraterone, and small interfering RNA
(siRNA) against CYP17A1were used to block CYP17A1 enzyme activity. The antiandrogen
RD162 was used to assess androgen receptor (AR) involvement. Cell growth was
measured by 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide assay. AR‐
target gene expression was quantified by reverse transcription polymerase chain reaction
(RT‐PCR). Nuclear import studies using cells with green fluorescent protein (GFP)‐tagged
AR were performed to assess the potential of precursor steroids to directly activate AR.
Results: Preg and Prog stimulated cell proliferation and AR target gene expression in
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VCaP, DuCaP, LNCaP, and their respective CRPC sublines. The antiandrogen RD162,
but not CYP17A1 inhibition with TAK700, abiraterone or siRNA, was able to block
Preg‐ and Prog‐induced proliferation. In contrast to TAK700, abiraterone also
affected dihydrotestosterone‐induced cell growth, indicating direct AR binding.
Furthermore, Prog‐induced AR translocation was not affected by treatment with
TAK700 or abiraterone, while it was effectively blocked by the AR antagonist
enzalutamide, further demonstrating the direct AR activation by Prog.
Conclusion: Activation of the AR by clinically relevant levels of Preg and Prog
accumulating in abiraterone‐treated patients may act as a driver for CRPC. These
data provide a scientific rationale for combining CYP17A1 inhibitors with antiandro-
gens, particularly in patients with overexpressed or mutated‐AR.
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1 | INTRODUCTION
Castration‐resistant prostate cancer (CRPC) continues to rely on
androgen receptor (AR) signaling for its growth, evidenced by the
majority of patients with CRPC still responding to novel AR signaling
pathway targeted agents. Both the antiandrogen enzalutamide (Xtan-
di),1,2 the specific inhibitor of the steroidogenic enzyme cytochrome
P450c17 (encoded by cytochrome P450, family 17, subfamily A,
polypeptide 1 [CYP17A1]), abiraterone acetate (Zytiga), a 17‐α hydro-
xylase and 17,20‐lyase specific enzyme inhibitor blocking steroidal
synthesis from androgen precursors3,4 demonstrated survival benefit in
patients with CRPC both in the pre‐ and in postdocetaxel treatment
settings. Moreover, two recently published trials have reported benefit
by combining abiraterone acetate with androgen deprivation therapy
(ADT) vs ADT alone in metastatic hormone‐sensitive prostate cancer.5,6
In contrast, the selective 17,20‐lyase inhibitor TAK700 (Orteronel])7
failed to demonstrate a survival benefit in either the pre‐ or
postdocetaxel setting.8,9 With novel hormonal agents now becoming
the mainstay of advanced prostate cancer (PC) therapy in both
hormone‐naïve and castration‐resistant setting, it is of importance to
identify resistance mechanisms to these agents.
Clinical data have shown that a subgroup of patients with CRPC
progressing on abiraterone still responds to enzalutamide,10 suggest-
ing that the AR signaling axis is still active in these patients despite
low circulating androgen levels.11 Several hypotheses have been
postulated on the origin of AR reactivation in CRPC and CYP17A1‐
inhibitor resistant disease. Indeed, Chen et al12 found the T877A AR
mutation, rendering the AR activatible to progestagens, in 3 of 18
clinical abiraterone‐resistant CRPC samples. Romanel et al13 showed
that not only AR gene modifications but also wild‐type AR copy
number gain were associated with poor response to abiraterone and
impaired overall survival. In addition, expression of the ligand‐
independent AR variant V7 has been associated with a poor response
to both enzalutamide and abiraterone.14
Preclinical studies have postulated CYP17A1‐dependent intratumoral
de novo steroid synthesis as a driver of CRPC and CYP17A1‐inhibitor
resistant disease. These studies reported de novo dihydrotestosterone
(DHT) synthesis in LNCaP and VCaP cell lines15,16,19 and reduced AR
target gene expression and DHT and T levels in CRPC xenograft tissue
after abiraterone treatment.18 In contrast, we and others have found
little evidence for de novo androgen synthesis in clinical CRPC samples.
Moreover, we have previously shown that androgen precursors induced
cell growth and AR target gene expression in vitro, but with undetectable
CYP17A1‐dependent conversion into testosterone, indicating either
direct AR binding or conversion rather than de novo synthesis as a
driver of cell growth.23
In the present study, we assessed if CRPC cell growth could be
driven by androgen precursors (pregnenolone [Preg] and progesterone
[Prog]) at clinically relevant levels found in aging men24 as well as in
patients treated with abiraterone.25,26 We used CRPC models
expressing wild‐type AR as well as mutated‐AR. Cell growth was
studied in the presence of CYP17A1 enzyme‐ and AR‐inhibitors. To
further establish the effects of precursor steroids on AR signaling, AR
translocation was evaluated using a fluorescently labeled wild‐type AR.
2 | MATERIALS AND METHODS
2.1 | Cell culture
VCaP (a kind gift from Dr KJ Pienta, Baltimore, MD) and DuCaP (kindly
provided and authenticated by Dr JA Schalken, Nijmegen, NL), both
carrying wild‐type AR, were grown in Roswell Park Memorial Institute
(RPMI) 1640 (Cambrex BioWhittaker, Wiesbaden, Germany) with 10%
fetal calf serum (FCS) and antibiotics. Hep3B stably expressing the
green fluorescent protein (GFP)‐AR27 were cultured in alpha minimum
essential medium (Cambrex BioWhittaker) with 5% FCS, 2mM
L‐glutamine (Cambrex BioWhittaker), and antibiotics. PC346C (wild‐
type AR) were maintained in prostate growth medium (PGM) based on
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Dulbecco’s modified Eagle’s medium (DMEM)‐F12 medium with several
PC growth factors and antibiotics as described in Marques et al28
supplemented with 2% FCS (PAN Biotech, Aidenbach, Germany) and
0.1 nM of the synthetic androgen R1881 (NEN, Boston, MA). PC346
FLU1 (wild‐type AR) and PC346C FLU2 (ART877A) cells were
maintained in PGM supplemented with 2% dextran‐coated charcoal‐
stripped FCS (DCC) instead of FCS, without R1881 and with the
addition 1 μM of hydroxyflutamide. LNCaP cells (ART877A; American
Type Culture Collection [ATCC], Manassas, VA) were maintained in
RPMI supplemented with 5% FCS and antibiotics. The adrenal cancer
cell line H295R (ATCC) was maintained in DMEM‐F12 supplemented
with 5% FCS and antibiotics. The cell lines PC346C, PC346C FLU1, and
PC346C FLU2 were generated in our laboratory and are authenticated
and described in Marques et al.28 PC346C‐GFP‐AR has been described
in van Soest et al.29 For all experiments, cells were used within 6
months of resuscitation from cryopreservation. After completion of
experiments, VCaP, LNCaP, and H295R were additionally verified by
short tandem repeat genotyping using the Promega Powerplex 16
system (Madison, WI) in November 2014.
2.2 | Establishment of CRPC cell lines
VCaP and DuCaP cells were cultured in RPMI with 10% DCC to
deplete the serum from steroids in the presence of antiandrogens
bicalutamide (1 μM) or hydroxyflutamide (1 μM), with n = 10 per
condition for >20 months to generate a panel of castration‐resistant
clones. When cell growth resembled that of the parental cells
growing under standard culture conditions, clones were considered
CRPC. For current experiments, clones expressing elevated levels of
wild‐type AR and CYP17A1 compared with parental lines were
selected for further experiments without further authentication.
2.3 | Cell proliferation assays
For cell proliferation assays, 5,000 cells per well were plated in 96‐
well dishes in their respective medium with DCC. After overnight
attachment, the synthetic androgen R1881, steroids, and compounds
were added to reach the indicated concentrations in a final volume of
200 μL. After 9 days, cell proliferation was assessed by
3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT)‐
assay as described previously.30
2.4 | Steroids and compounds
For cell culture assays, RD162, a nonsteroidal antiandrogen was
used (Merck, Oss, Netherlands). It is closely related to and was
selected from the same drug‐screen as MDV3100 (enzalutamide). In
vitro and in vivo, it has equal potency in AR‐antagonism as
enzalutamide and no significant difference in bioavailability in
preclinical testing.31 For AR binding assays, enzalutamide (Axon
Medchem, Groningen, The Netherlands) was used because of its
current use in clinical practice.
Steroids were obtained from Steraloids (Newport, RI) and dissolved
in ethanol. RD162, enzalutamide, TAK700 (Millennium Pharmaceuticals,
Cambridge) or abiraterone (Johnson & Johnson, New Brunswick) were
all dissolved in dimethyl sulfoxide (DMSO). Similar amounts of DMSO
(0.1%) were added to control cells. Concentrations used were based on
levels reported in Belanger et al24,25 and Taplin et al26 (summarized in
Table S1).
2.5 | Δ4‐Androstenedione analysis
H295R cells at 100.000 cells per well were seeded into 24‐well tissue
culture plates and allowed to attach overnight in medium with FCS,
after which medium was replaced by the serum‐free medium with or
without the CYP17A1 inhibitors TAK700 (Millennium Pharmaceuticals)
or abiraterone (Johnson & Johnson) for 48 hours. Medium from wells
without cells served as blanks. Three replicates were used per
condition. After 48 hours of culture, the medium was collected and
frozen at −20°C. Δ4‐Androstenedione concentrations were determined
using the IMMULITE 2000 automated assay system (Siemens DPC, Los
Angeles, CA) with a detection limit of 1.05 nM. The results are shown
as means ± SE of three independent experiments. Inhibitory concentra-
tion (IC50) values were determined by nonlinear regression using the
GraphPad Prism software with Y = 100/(1 + 10X−logIC50).
2.6 | CYP17A1 knockdown
After overnight attachment, cells were transfected with CYP17A1 or
nontargeting small interfering RNA (siRNA; On‐TARGETplus
SMARTpool siRNA; Dharmacon, Lafayette, LA) using Lipofectamine
RNAiMax (Invitrogen, Carlsbad, CA) according to the manufacturer’s
instructions. Twenty‐four hours after transfection, the medium was
replaced by DCC medium with indicated steroids. RNA was isolated
after 48 hours or proliferation determined at day 6.
2.7 | Gene expression analysis
For quantitative polymerase chain reaction (qPCR) studies, RNA was
isolated using RNA‐Bee (TEL‐TEST Inc, Friendswood, TX) from
cultures treated for 48 hours with indicated compounds/steroids,
24 hours after seeding in DCC medium at 100.000 cells per well.
Reverse transcriptase and qPCR runs were performed as described
previously21 using an ABI Prism 7900 Sequence Detection System
under standard conditions. Complementary DNA (cDNA; 20 ng) was
amplified in SYBR Green PCR Master Mix (Applied Biosystems,
Foster City, CA) or TaqMan Universal Master Mix (Applied
Biosystems). PCR efficiency was verified by cDNA dilution curves
and exceeding 90% for all assays. Primer/probe sets used are noted
in Table S2. Gene expression was calculated as fold expression over
housekeeping genes GAPDH or PBGD and vehicle treated cells.
2.8 | Nuclear AR import studies
Nuclear translocation of the AR has been studied in time as well as in
end‐point measurements using fluorescence confocal microscopy on
MOLL ET AL. | 939
PC346C cells stably expressing enhanced green fluorescent protein
(EGFP)‐AR.29 To measure the effect of a concentration range of Preg
and Prog, cells were seeded in a glass bottom 96‐well plate in culture
medium supplemented with the charcoal‐stripped serum to avoid
premature AR activation. Sixteen hours before imaging enzalutamide,
TAK700, abiraterone (1 μM), and DMSO carrier only as control were
added. Subsequently, 4 hours before imaging potential AR transloca-
tion was initiated using 0, 1, 10, and 100 nM Preg or Prog, and with
0.1 and 1 nM R1881 as the positive control, and nuclei were stained
with Hoechst for reference. Cells were imaged using the Opera
Phenix HCS system equipped with an x40 water immersion objective.
Hoechst and EGFP were exited using 405 and 488 nm lasers and
were visualized using 435 to 480 nm and 500 to 550 nm band‐pass
filters. EGFP intensities were measured in the nuclear (nuc) and the
peri‐nuclear (cyto) regions. Nuclear translocation of the AR was
expressed by nuclear signal intensity/(nuclear signal intensity+cyto-
plasmatic signal intensity), after background subtraction.
The ratio of AR nuclear localization was expressed as:
For the analysis of AR‐translocation dynamics, cells were seeded on
glass coverslips in six‐well plates. After overnight attachment, cells were
treated with TAK700 (3 µM) or vehicle for 12 hours and subsequently
transferred to a live‐cell chamber and maintained at 37°C and 5% CO2.
Time‐lapse imaging was performed using a Zeiss LSM510 confocal
microscope (Carl Zeiss, Jena, Germany), equipped with a 63 × 1.3 NA oil
(A)
(B)
(C)
F IGURE 1 AR‐blockade, but not CYP17A1 inhibition reduced Preg‐ and Prog‐induced cell growth in CRPC clones of VCaP and DuCaP. A,
VCaP CRPC derivatives BIC‐B and FLU‐D and DuCaP CRPC derivative BIC‐H were plated in DCC medium and incubated with vehicle (ethanol,
white), Preg (light gray), Prog (dark gray), or DHT (black) at the indicated levels. Data are expressed as mean ± SE of three independent
experiments. DuCaP BIC‐H appeared hypersensitive to androgens, growing even better with Preg or Prog as compared with DHT. B, VCaP BIC‐
B and FLU‐D and DuCaP BIC‐H were incubated with 10 nM of Preg or Prog, or with 0.1 nM DHT with or without 1 μM of the antiandrogen
RD162. Data shown are mean ± SE of four independent experiments. C, VCaP BIC‐B and FLU‐D and DuCaP BIC‐H were treated with 100 nM of
Preg or Prog or with 0.1 nM DHT with or without TAK700 at the indicated concentrations. Data shown are mean ± SE of three independent
experiments. *P < 0.05, **P < 0.01, ***P < 0.001. AR, androgen receptor; CRPC, castration‐resistant prostate cancer; CYP17A1, cytochrome
P450, family 17, subfamily A, polypeptide 1; DCC, dextran‐coated charcoal‐stripped fetal calf serum; DHT, dihydrotestosterone; Preg,
pregnenolone; Prog, progesterone
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FIGURE 2 Continued.
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immersion objective. EGFP‐AR was visualized using 488 nm excitation
of an Argon‐laser line and detection of emission between 500 and
530 nm. For time‐lapse imaging, images were acquired with 5minutes
interval during 130minutes at multiple locations of the same sample.
After 5 to 10minutes of imaging, Prog (100 nM), Preg (100 nM), or
R1881 (1 nM) was added to the medium to investigate AR nuclear
translocation. Average fluorescence intensities in the nucleus and
cytoplasm were measured at every time point.
2.9 | Data analysis
MTT and qPCR results were normalized to control and compared
using the two‐sided Student t test. AR translocation was analyzed
using one‐way analysis of variance (ANOVA) with subsequent
Tukey’s multiple comparisons on logarithmically transformed values
to equalize variances. Analyses were carried out using the GraphPad
Prism version 5.03 (GraphPad Software, San Diego, CA). P < 0.05 was
considered statistically significant.
3 | RESULTS
3.1 | CYP17A1 inhibitors abiraterone and TAK700
effectively inhibit steroidogenesis in H295R cells
To determine IC50 values of the CYP17A1 inhibitors under the
conditions used in this study, human adrenal H295R cells were
incubated in steroid stripped medium with increasing amounts of
abiraterone or TAK700. Δ4‐Androstenedione synthesis—which is
directly dependent on CYP17A1 activity (Figure S1A)—was effec-
tively blocked in H295R cells (expressing CYP17A1 1100‐fold vs
prostate cells) with IC50 values of 15.5 (95% confidence interval [CI],
10.4‐23.0) and 67.7 (95% CI, 58.6‐78.1) nM for abiraterone and
TAK700, respectively (Figure S1B).
3.2 | Preg‐ and Prog‐mediated cell growth of CRPC
clones is independent of CYP17A1 enzymatic activity
To assess the biological relevance of CYP17A1‐mediated cell growth in
CRPC, we selected CRPC cell lines of VCaP (BIC‐B and FLU‐D,
resistant to bicalutamide and flutamide, respectively) and DuCaP (BIC‐
H) based on their elevated CYP17A1 and AR gene expression level
compared with their parental cell lines (Table S3). Preg and Prog at
levels of 1 nM and upstimulated cell growth in all CRPC clones tested
(Figure 1A). RD162 effectively blocked 10 nM Prog‐ and Preg‐induced
cell growth (Figure 1B), indicating that the proliferative effects of Preg
and Prog were AR‐driven. Despite complete CYP17A1 inhibition as
demonstrated in H295R cells, TAK700 could not inhibit Preg‐ and
Prog‐induced cell growth in these CRPC clones in concentrations up to
10 μM, which is approximately 150 times the IC50 in our in vitro
conditions (Figure 1C). Preg‐ and Prog‐activated AR was confirmed by
upregulated expression of the AR‐target gene PSA in VCaP BIC‐B even
in the presence of TAK700 (Figure S2). Similar results were obtained
for LNCaP (Figure S3), and PC346C CRPC cells that are characterized
by an overexpressed wild‐type AR (PC346C FLU1) or by T877A AR
mutation (PC346C FLU2; Figure S4). Of note, CYP17A1 messenger
RNA (mRNA) could not be detected in LNCaP nor in PC346C (Table
S3). Also, we were unable to detect CYP17A1 protein in VCaP despite
detectable mRNA levels. (Figure S5). The AR‐driven effects in the
presence of TAK700 indicate that growth of these CRPC clones,
despite upregulated CYP17A1 mRNA, was not dependent on the
increased activity of de novo steroidogenesis.
Prog and Preg stimulate cell growth of castration‐naïve VCaP and
DuCaP cells via AR activation to test if Preg and Prog could also
facilitate cell growth of castration‐naïve parental VCaP and DuCaP,
characterized by relatively low levels of CYP17A1 (Table S3), cells were
incubated with 10 and 100 nM Prog and Preg. Indeed, cell growth was
significantly stimulated (Figure 2A) with concomitant induction of
AR target gene expression, although to a lesser extent than by DHT
(Figure 2B). One micrometer RD162 significantly blocked Prog‐ and
Preg‐induced VCaP and DuCaP cell growth (Figure 2C), substantiating
that the proliferative effect of Preg and Prog were AR‐driven.
Furthermore, TAK700 did not inhibit Preg‐ or Prog‐induced cell growth,
indicating the effect to be independent of CYP17A1 activity also in
hormone‐naïve PC cell lines (Figure 3A). Abiraterone affected Preg‐
stimulated but not Prog‐induced cell proliferation, and only at
concentrations exceeding the IC50 for CYP17A1 inhibition that also
blocked DHT‐induced cell growth (Figure 3B)
To further substantiate that cell growth in hormone‐naive PC cells is
independent of CYP17A1, VCaP, and DuCaP were treated with siRNA
for CYP17A1. Similarly to incubation with TAK700, treatment with
CYP17A1 siRNA—resulting in undetectable levels of CYP17A1 mRNA—
did not affect Prog stimulated levels of PSA mRNA in parental VCaP
(Figure 3C). Likewise, in DuCaP, Preg‐ and Prog‐induced cell prolifera-
tion was unaffected by CYP17A1‐directed siRNA (Figure 3D).
F IGURE 2 Preg‐ and Prog‐activated AR in VCaP and DuCaP. A, Castration‐naïve VCaP (left) and DuCaP (right) cells were treated with Preg
(light gray), Prog (dark gray), or DHT (black) at indicated concentrations (M). Data shown are mean ± SE of three independent experiments.
B, Castration‐naïve VCaP (left) and DuCaP (right) cells were treated with Preg or Prog or DHT for 48 hours at indicated concentrations (M), and
gene expression was assessed by qPCR with each sample in duplicate. Data shown are mean ± SE of three independent experiments. C, VCaP
and DuCaP cells were treated with 100 nM Preg or Prog of 0.1 nM with or without RD162. Cell growth was assessed by MTT assay on day 9.
Data shown are mean ± SEM of a minimum of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001. AR, androgen receptor;
CYP17A1, cytochrome P450, family 17, subfamily A, polypeptide 1; DCC, dextran‐coated charcoal‐stripped fetal calf serum; DHT,
dihydrotestosterone; Preg, pregnenolone; Prog, progesterone; qPCR, quantitative polymerase chain reaction
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FIGURE 3 Continued.
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3.3 | Preg and Prog translocate AR to the nucleus
without requiring conversion into testosterone
To prove the direct effects of Preg and Prog on wild‐type AR, AR
translocation to the nucleus was evaluated in Hep3B cells expressing
GFP‐tagged‐ARwt. Incubation with 100 nM Prog resulted in direct AR
translocation, despite preincubation with 3 μM TAK700 (~45 times
the IC50 of CYP17A1 inhibition in H295R cells; Figure S6). To
further substantiate these findings, we evaluated AR translocation in
the human prostate cancer cell line PC346C, which naturally
expresses ARwt and lacks CYP17A1 expression. Incubation with
Prog, but not Preg, induced translocation of AR to the nucleus in
PC346C cells stably transfected with GFP‐ARwt. This translocation
could not be inhibited by overnight preincubation with 1 μM TAK700
or abiraterone, but only by pretreatment with 1 μM of the AR
antagonist enzalutamide (Figure 4), indicating that these effects were
indeed dependent on direct activation of AR.
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F IGURE 4 CYP17A1 inhibitors TAK700 and abiraterone are unable to inhibit progesterone‐induced AR translocation. Top, representative
images of PC346C‐GFP‐AR cells 3 hours after the addition of vehicle control (ethanol) or increasing levels of Preg or Prog, with each row
showing representative images after pretreatment with either DMSO, 1 μM TAK700, 1 μM abiraterone or 1 μM enzalutamide. Bottom,
representative images 3 hours after addition of negative control (ethanol+DMSO) or positive control: 1 nM R1881+DMSO. Scale bar = 40 μm.
The number in the top‐left of each picture indicates average nuclear/total AR signal ratio. Corresponding graph bars with SD are provided in
Figure S7. AR, androgen receptor; CYP17A1, cytochrome P450, family 17, subfamily A, polypeptide 1; DMSO, dimethyl sulfoxide; GFP, green
fluorescent protein; Preg, pregnenolone; Prog, progesterone
F IGURE 3 Preg‐ and Prog‐induced cell growth of castration‐naïve VCaP and DuCaP is independent of CYP17A1 activity. Cells were treated
with 100 nM of Preg (light gray) or Prog (dark gray), or 0.1 nM DHT (black) with or without TAK700 (A) or abiraterone (B) at indicated
concentrations. Data shown are mean ± SE of three independent experiments. C, VCaP cells were transfected with 2.5 or 5 nM CYP17A1‐
directed or 5 nM scrambled siRNA (Dharmacon) for 24 hours, after which cells were incubated with vehicle or 100 nM Prog for 48 hours after
which CYP17A1 and PSA mRNA expression were assessed by qPCR with each sample in duplicate. D, DuCaP cells were transfected with 2.5 or
5 nM CYP17A1 siRNA or 5 nM scrambled siRNA (Dharmacon) for 24 hours and subsequently incubated with Preg, Prog, or vehicle (ethanol) for
6 days. Cell proliferation was assessed by MTT assay. Data shown are mean ± SE of three independent experiments. *P < 0.05, **P < 0.01,
***P < 0.001. AR, androgen receptor; CYP17A1, cytochrome P450, family 17, subfamily A, polypeptide 1; DCC, dextran‐coated charcoal‐stripped
fetal calf serum; DHT, dihydrotestosterone; mRNA, messenger RNA; Preg, pregnenolone; Prog, progesterone; qPCR, quantitative polymerase
chain reaction; siRNA, small interfering RNA
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4 | DISCUSSION
Here, we show that clinically relevant levels of androgen precursors
Preg and Prog stimulated cell growth of parental VCaP and DuCaP
and of their respective CRPC cell lines that are characterized by
overexpressed levels of wild‐type AR and CYP17A1. These precursors
have been shown to commonly accumulate in patients during
CYP17A1 therapy. This growth induction could be effectively
blocked by the potent AR antagonist RD162, but not by CYP17A1‐
specific inhibition by TAK700, abiraterone or by siRNA. These cell
growth effects were paralleled by the induction of AR target gene
expression, indicating these effects were AR‐driven. Similar results
were observed in LNCaP and the flutamide‐resistant CRPC cell line
PC346 FLU2, which both carry the T877A mutation in the ligand‐
binding domain of the AR, but also in the flutamide‐resistant CRPC
cell line PC346 FLU1, which overexpresses wild‐type AR. Together,
these results suggest a common mechanism of androgen precursor‐
induced cell growth in AR‐overexpressing CRPC that drives cell
growth independent of de novo androgen synthesis through
CYP17A1, but via direct AR‐stimulation. Our AR nuclear import
studies further supported Preg and Prog to be able to directly
activate wild‐type AR. These data provide an alternative mechanism
of (CYP17A1‐induced) CRPC resistance that is driven by accumulat-
ing precursor androgens that may directly mediate AR‐regulated cell
growth, particularly in tumors overexpressing AR. Indeed, recent
studies on cell‐free DNA in patients with metastatic CRPC have
demonstrated that AR copy number gain at the initiation of
treatment with second‐line hormonal agents is indicative of primary
resistance to these agents.13,32
Data on precursor steroid levels in patients treated with
abiraterone are scarce. As a surrogate measure of systemic steroid
concentrations, urinary Preg and Prog metabolites in patients treated
with abiraterone without exogenous glucocorticoids have previously
been shown reported to be 2.5 to 44 and 3.8 to 61 times higher
compared with baseline.25 In patients treated with concomitant
glucocorticoids, serum levels of Preg and Prog decreased markedly
(Table S1). Taplin et al26 reported intraprostatic steroid tissue
concentrations from prostate biopsies in patients undergoing
neoadjuvant castration in combination with abiraterone and pre-
dnisone before radical prostatectomy. As expected, intratumour
androgen concentrations decreased dramatically, but with the
consequence of increasing levels of the CYP17A1 substrates Preg
and Prog (mean for Preg, 142 nM; Prog, 1 nM). These levels were
comparable to levels that demonstrated growth induction in our
CRPC models.
With CYP17A1 expression being a magnitude lower in prostate
cells compared with adrenal cells (Figure S4 and Luu ‐The et al33) and
TAK700 and abiraterone inhibiting CYP17A1 in human adrenal
H295R cells at 67 and 15 nM, respectively, the steroid synthesis
inhibitor levels used in this study should effectively inhibit CYP17A1
activity in prostate cells. The fact that neither clinically relevant
levels of TAK700 (up to 6 μM34), abiraterone (up to 2 μM35) nor
siRNA against CYP17A1 were able to reverse Preg‐ or Prog‐induced
cell growth of CRPC at clinically relevant levels shown in our study
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F IGURE 5 Schematic representation of alternative mechanisms of CRPC. Simplified overview of the classical androgen synthesis pathway.
Thick arrows indicate the preferred steps in human androgen biosynthesis and subsequent AR activation as reported in the literature.
Abiraterone and TAK700 effectively inhibit steroid synthesis, but cannot prevent direct binding of the steroid precursors Preg or Prog to the
AR (dotted line). Direct AR‐antagonism by enzalutamide will still block activation by either DHT or Prog. AR, androgen receptor; CRPC,
castration‐resistant prostate cancer; CYP17A1, cytochrome P450, family 17, subfamily A, polypeptide 1; DHT, dihydrotestosterone; Preg,
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underscore reports that intratumoral de novo steroidogenesis is not
essential for CRPC growth.36
We demonstrate that inhibition of AR‐mediated cell growth by
abiraterone can be (partly) explained by direct AR‐antagonism, albeit
at peak concentrations. This is consistent with data that abiraterone
can bind to and antagonize AR in LNCaP and VCaP,37,38 and our prior
report that abiraterone can also partially block AR nuclear
translocation.29 Furthermore, the previously observed 3βHSD
inhibition,39 combined with the antiandrogenic potency and inhibi-
tion of CYP17A1, 3βHSD, and SRD5A by the abiraterone metabolite,
D4‐abiraterone,40 may explain the beneficial effect of abiraterone in
clinical trials relative to TAK700, which seems to lack these
additional effects.
To date, two retrospective studies reported PSA response rates
of 27% and 30% for enzalutamide in abiraterone progressive
patients.41,42 Interestingly, in a third retrospective study, PSA
responses for enzalutamide after abiraterone vs abiraterone after
enzalutamide have been reported to be higher (30% vs 6%), with a
trend towards longer PFS in the first group.43 In contrast, adding
abiraterone to continued enzalutamide treatment did not result in a
significant delay of PSA progression vs abiraterone alone in patients
with biochemical progression on enzalutamide.44 However, none of
these studies have interrogated the upfront combination of AR‐
antagonism with androgen synthesis inhibition.
Although our study may be limited by the use of in vitro models, it
is important to note that these different cell lines were selected
based on highly clinically relevant characteristics, including the
absence of intratumoral CYP17A1 expression in the context of high
AR expression. The studies were performed using clinically relevant
levels of steroids and drugs as reported from relevant patient
cohorts, to recapitulate the negative consequences of enhanced
substrate levels of preg and prog in patients with CRPC treated with
CYP17A1 inhibitors. The in vitro system allows for defined
assessment of the potential of different steroids that will otherwise
be obscured in in vivo models. These data provide basic mechanistic
evidence to combine steroid synthesis inhibition with antiandrogens
to fully extinguish ligand‐dependent AR activation in tumors that
have become hypersensitive to minute levels of androgen or
alternative steroidal ligands (like accumulating progestagens due to
systemic CYP17A1 inhibition) via AR amplification or mutations in
the absence of intratumoral CYP17A1 activity. Thus, prospective
data on PSA response and possible survival benefit of combining
abiraterone with enzalutamide from the start of second‐line
hormonal therapy are eagerly awaited.45
5 | CONCLUSIONS
In summary, our study demonstrates that in castration‐naïve and CRPC
cell lines, androgen precursor steroids Preg and Prog are able to directly
activate wild‐type and mutated‐AR, independent of CYP17A1‐mediated
conversion into testosterone (Figure 5). These findings may indicate a
mechanism of resistance for patients progressing on CYP17A1 therapy
where enzyme inhibition causes accumulation of these androgen
precursors, and provide an explanation of why CYP17A1‐inhibitor‐
resistant tumors may still respond to treatment with antiandrogens.
From a clinical perspective, these data support the rationale for the
combination of CYP17‐inhibitors with potent antiandrogens, to
effectively suppress AR activation mediated by accumulating steroidal
ligands in both AR‐amplified and AR‐mutated tumors.
ACKNOWLEDGMENTS
This study was supported by an investigator initiated research grant
from Millennium Pharmaceuticals, Inc and an institutional grant from
the Erasmus MC (MRace 2008).
CONFLICT OF INTERESTS
RW receives consultancy and speaker fees from Sanofi, Millennium,
Merck, Roche. RS receives speaker fee from Sanofi, Janssen
Pharmaceuticals. WW receives grant supports from Sanofi, Millen-
nium, Janssen Pharmaceuticals, Servier.
ORCID
Jan M. Moll http://orcid.org/0000-0003-1520-3911
Wytske M. Weerden http://orcid.org/0000-0003-0324-4804
REFERENCES
1. Scher HI, Fizazi K, Saad F, et al. Increased survival with
enzalutamide in prostate cancer after chemotherapy. N Engl
J Med. 2012;367(13):1187‐97.
2. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in
metastatic prostate cancer before chemotherapy. N Engl J Med.
2014;371(5):424‐33.
3. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased
survival in metastatic prostate cancer. N Engl J Med. 2011;
364(21):1995‐2005.
4. Rathkopf DE, Smith MR, de Bono JS, et al. Updated interim efficacy
analysis and long‐term safety of abiraterone acetate in metastatic
castration‐resistant prostate cancer patients without prior che-
motherapy (COU‐AA‐302). Eur Urol. 2014;66:815‐825.
5. James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate
cancer not previously treated with hormone therapy. N Engl J Med.
2017;377(4):338‐351.
6. Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in
metastatic, castration‐sensitive prostate cancer. N Engl J Med.
2017;377:352‐360.
7. Yamaoka M, Hara T, Hitaka T, et al. Orteronel (TAK‐700), a novel
non‐steroidal 17,20‐lyase inhibitor: effects on steroid synthesis in
human and monkey adrenal cells and serum steroid levels in
cynomolgus monkeys. J Steroid Biochem Mol Biol. 2012;129(3‐5):
115‐28.
8. Saad F, Fizazi K, Jinga V, et al. Orteronel plus prednisone in patients
with chemotherapy‐naive metastatic castration‐resistant prostate
cancer (ELM‐PC 4): a double‐blind, multicentre, phase 3, randomised,
placebo‐controlled trial. Lancet Oncol. 2015;16(3):338‐348.
9. Fizazi K, Jones R, Oudard S, et al. Phase III, randomized, double‐blind,
multicenter trial comparing orteronel (TAK‐700) plus prednisone
946 | MOLL ET AL.
with placebo plus prednisone in patients with metastatic castration‐
resistant prostate cancer that has progressed during or after
docetaxel‐based therapy: ELM‐PC 5. J Clin Oncol. 2015;33(7):723‐31.
10. Schrader AJ, Boegemann M, Ohlmann CH, et al. Enzalutamide in
castration‐resistant prostate cancer patients progressing after
docetaxel and abiraterone. Eur Urol. 2014;65(1):30‐36.
11. Ryan CJ, Peng W, Kheoh T, et al. Androgen dynamics and serum PSA
in patients treated with abiraterone acetate. Prostate Cancer Prostatic
Dis. 2014;17:192‐198.
12. Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in
castration‐resistant prostate cancer selects for progesterone respon-
sive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273‐80.
13. Romanel A, Gasi Tandefelt D, Conteduca V, et al. Plasma AR
and abiraterone‐resistant prostate cancer. Sci Transl Med. 2015;
7(312):312re10.
14. Antonarakis ES, Lu C, Wang H, et al. AR‐V7 and resistance to
enzalutamide and abiraterone in prostate cancer. N Engl J Med.
2014;371(11):1028‐38.
15. Locke JA, Guns ES, Lubik AA, et al. Androgen levels increase by
intratumoral de novo steroidogenesis during progression of castra-
tion‐resistant prostate cancer. Cancer Res. 2008;68(15):6407‐6415.
16. Cai C, Chen S, Ng P, et al. Intratumoral de novo steroid synthesis
activates androgen receptor in castration‐resistant prostate cancer
and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res.
2011;71(20):6503‐13.
17. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of
intratumoral androgens in metastatic prostate cancer: a mechanism
for castration‐resistant tumor growth. Cancer Res. 2008;68(11):
4447‐4454.
18. Mostaghel EA, Marck BT, Plymate SR, et al. Resistance to CYP17A1
inhibition with abiraterone in castration‐resistant prostate cancer:
induction of steroidogenesis and androgen receptor splice variants.
Clin Cancer Res. 2011;17(18):5913‐25.
19. Dillard PR, Lin MF, Khan SA. Androgen‐independent prostate
cancer cells acquire the complete steroidogenic potential of
synthesizing testosterone from cholesterol. Mol Cell Endocrinol. 2008;
295(1‐2):115‐20.
20. Jernberg E, Thysell E, Bovinder Ylitalo E, et al. Characterization of
prostate cancer bone metastases according to expression levels of
steroidogenic enzymes and androgen receptor splice variants. PLoS
One. 2013;8(11):e77407.
21. Hofland J, van Weerden WM, Dits NFJ, et al. Evidence of limited
contributions for intratumoral steroidogenesis in prostate cancer.
Cancer Res. 2010;70(3):1256‐64.
22. Fankhauser M, Tan Y, Macintyre G, et al. Canonical androstenedione
reduction is the predominant source of signalling androgens in hormone
refractory prostate cancer. Clin Cancer Res. 2014;20:5547‐5557.
23. Shinkai Y, Yamanaka I, Duong HHT, Quynh NT, Kanaho Y, Kumagai Y.
Garcinia vilersiana bark extract activates the Nrf2/HO‐1 signaling
pathway in RAW264.7 cells. J Toxicol Sci. 2013;38(6):875‐878.
24. Belanger A, Candas B, Dupont A, et al. Changes in serum
concentrations of conjugated and unconjugated steroids in 40‐ to
80‐year‐old men. J Clin Endocrinol Metab. 1994;79(4):1086‐90.
25. Attard G, Reid AHM, Auchus RJ, et al. Clinical and biochemical
consequences of CYP17A1 inhibition with abiraterone given with and
without exogenous glucocorticoids in castrate men with advanced
prostate cancer. J Clin Endocrinol Metab. 2012;97(2):507‐16.
26. Taplin ME, Montgomery B, Logothetis CJ, et al. Intense androgen‐
deprivation therapy with abiraterone acetate plus leuprolide acetate
in patients with localized high‐risk prostate cancer: results of a
randomized phase II neoadjuvant study. J Clin Oncol. 2014;32(33):
3705‐15.
27. Farla P, Hersmus R, Geverts B, et al. The androgen receptor ligand‐
binding domain stabilizes DNA binding in living cells. J Struct Biol.
2004;147(1):50‐61.
28. Marques RB, van Weerden WM, Erkens‐Schulze S, et al. The human
PC346 xenograft and cell line panel: a model system for prostate
cancer progression. Eur Urol. 2006;49(2):245‐57.
29. van Soest RJ, van Royen ME, de Morrée ES, et al. Cross‐resistance
between taxanes and new hormonal agents abiraterone and
enzalutamide may affect drug sequence choices in metastatic
castration‐resistant prostate cancer. Eur J Cancer. 2013;49(18):
3821‐3830.
30. Romijn JC, Verkoelen CF, Schroeder FH. Application of the MTT
assay to human prostate cancer cell lines in vitro: establishment of
test conditions and assessment of hormone‐stimulated growth and
drug‐induced cytostatic and cytotoxic effects. Prostate. 1988;12(1):
99‐110.
31. Tran C, Ouk S, Clegg NJ, et al. Development of a second‐generation
antiandrogen for treatment of advanced prostate cancer. Science.
2009;324(5928):787‐90.
32. Conteduca V, Wetterskog D, Sharabiani MTA, et al. Androgen
receptor gene status in plasma DNA associates with worse outcome
on enzalutamide or abiraterone for castration‐resistant prostate
cancer: a multi‐institution correlative biomarker study. Ann Oncol.
2017;28(7):1508‐1516.
33. Luu‐The V. Assessment of steroidogenesis and steroidogenic enzyme
functions. J Steroid Biochem Mol Biol. 2013;137:176‐82.
34. Dreicer R, MacLean D, Suri A, et al. Phase I/II trial of orteronel (TAK‐
700)‐‐an investigational 17,20‐lyase inhibitor‐‐in patients with meta-
static castration‐resistant prostate cancer. Clin Cancer Res.
2014;20(5):1335‐44.
35. Ryan CJ, Smith MR, Fong L, et al. Phase I clinical trial of the CYP17
inhibitor abiraterone acetate demonstrating clinical activity in
patients with castration‐resistant prostate cancer who received prior
ketoconazole therapy. J Clin Oncol. 2010;28(9):1481‐1488.
36. Kosaka T, Miyajima A, Yasumizu Y, Miyazaki Y, Kikuchi E, Oya M.
Limited in vitro efficacy of CYP17A1 inhibition on human castration
resistant prostate cancer. Steroids. 2014;92:39‐44.
37. Soifer HS, Souleimanian N, Wu S, et al. Direct regulation of androgen
receptor activity by potent CYP17 inhibitors in prostate cancer cells.
J Biol Chem. 2012;287(6):3777‐87.
38. Richards J, Lim AC, Hay CW, et al. Interactions of abiraterone,
eplerenone, and prednisolone with wild‐type and mutant androgen
receptor: a rationale for increasing abiraterone exposure or combin-
ing with MDV3100. Cancer Res. 2012;72(9):2176‐2182.
39. Li R, Evaul K, Sharma KK, et al. Abiraterone inhibits 3beta‐
hydroxysteroid dehydrogenase: a rationale for increasing drug
exposure in castration‐resistant prostate cancer. Clin Cancer Res.
2012;18(13):3571‐3579.
40. Li Z, Bishop AC, Alyamani M, et al. Conversion of abiraterone to
D4A drives anti‐tumour activity in prostate cancer. Nature. 2015;
523:347‐351.
41. de Bono JS, Chowdhury S, Feyerabend S, et al. Antitumour activity
and safety of enzalutamide in patients with metastatic castration‐
resistant prostate cancer previously treated with abiraterone
acetate plus prednisone for ≥24 weeks in Europe. Eur Urol.
2018;74(1):37‐45.
42. Emamekhoo H, Barata PC, Edwin NC, Woo KM, Grivas P, Garcia JA.
Evaluation of response to enzalutamide consecutively after abirater-
one acetate/prednisone failure in patients with metastatic castration‐
resistant prostate cancer. Clin Genitourin Cancer. 2018;16:429‐436.
43. Matsubara N, Yamada Y, Tabata K, et al. Abiraterone followed by
enzalutamide versus enzalutamide followed by abiraterone in
chemotherapy‐naive patients with metastatic castration‐resistant
prostate cancer. Clin Genitourin Cancer. 2018;16(2):142‐148.
44. Attard G, Borre M, Gurney H, et al. Abiraterone alone or in
combination with enzalutamide in metastatic castration‐resistant
prostate cancer with rising prostate‐specific antigen during enzalu-
tamide treatment. J Clin Oncol. 2018;36(25):2639‐2646.
MOLL ET AL. | 947
45. Attard G, Sydes MR, Mason MD, et al. Combining enzalutamide with
abiraterone, prednisone, and androgen deprivation therapy in the
STAMPEDE trial. Eur Urol. 2014;66(5):799‐802.
SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
How to cite this article: Moll JM, Kumagai J, van Royen ME,
et al. A bypass mechanism of abiraterone‐resistant prostate
cancer: Accumulating CYP17A1 substrates activate androgen
receptor signaling. The Prostate. 2019;79:937‐948.
https://doi.org/10.1002/pros.23799
948 | MOLL ET AL.
